Nobukazu Tanaka

Induction chemotherapy with paclitaxel, carboplatin and cetuximab for locoregionally advanced nasopharyngeal carcinoma: A single-center, retrospective study

T. Akimoto, M. Tahara, S. Zenda, 2022, Frontiers in Oncology.

Impact of tumor burden on survival in patients with recurrent or metastatic head and neck cancer treated with immune checkpoint inhibitors

D. Kawakita, Takuma Matoba, Kiyoshi Minohara, 2022, Scientific Reports.

Biweekly administration of cetuximab in Japanese patients with recurrent or metastatic head and neck cancer

T. Fujisawa, M. Tahara, S. Okano, 2022, International Journal of Clinical Oncology.

Biweekly administration of cetuximab in Japanese patients with recurrent or metastatic head and neck cancer

T. Fujisawa, M. Tahara, S. Okano, 2022, International Journal of Clinical Oncology.

Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab

A. Murashima, Taijiro Ozawa, D. Kawakita, 2021, Scientific Reports.

Potential efficacy of local therapy for progressive lesions after nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

T. Akimoto, K. Matsuura, M. Tahara, 2023, International Journal of Clinical Oncology.

集学的治療を行った鼻腔粘膜悪性黒色腫の臨床的検討

T. Sanuki, D. Kawakita, H. Tsuge, 2023, Nippon Jibiinkoka Tokeibugeka Gakkai Kaiho(Tokyo).

Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

M. Tahara, S. Okano, Yuri Ueda, 2023, European journal of cancer.